Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Stemline Therapeutic (STML)

Stemline Therapeutic (STML)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Stemline Therapeutics Highlights Recent Clinical and Regulatory Developments and Details Upcoming Milestones following its Annual Shareholder Meeting

Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, following its annual shareholder...

STML : 13.47 (-2.53%)
The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of Stemline Therapeutics, Inc. Common Stock -- STML

The Rosen Law Firm, P.A. announces that the United States District Court Southern District of New York has approved the following announcement of a proposed class action settlement that would benefit purchasers...

STML : 13.47 (-2.53%)
Stemline Therapeutics Announces ELZONRIS Clinical Data Selected for Presentation at Upcoming EHA Annual Congress

Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that ELZONRIS (tagraxofusp)...

STML : 13.47 (-2.53%)
Stemline Therapeutics Announces ELZONRIS Clinical Data Selected for Presentation at the Upcoming ASCO Annual Meeting

Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that ELZONRIS (tagraxofusp)...

STML : 13.47 (-2.53%)
Stemline Therapeutics (STML) Reports Q1 Loss, Tops Revenue Estimates

Stemline Therapeutics (STML) delivered earnings and revenue surprises of -8.96% and 93.82%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

STML : 13.47 (-2.53%)
Stemline Therapeutics: 1Q Earnings Snapshot

NEW YORK (AP) _ Stemline Therapeutics Inc. (STML) on Friday reported a loss of $27.4 million in its first quarter.

STML : 13.47 (-2.53%)
Stemline Therapeutics Reports First Quarter 2019 Financial Results

-- Net revenue for ELZONRIS was $5.05 million for the first quarter

STML : 13.47 (-2.53%)
Stemline Therapeutics to Host Conference Call on First Quarter 2019 Financial Results on May 10, 2019

Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that the company...

STML : 13.47 (-2.53%)
Repligen Corp is Among the Companies in the Biotechnology Industry with the Best Relative Performance (RGEN , LXRX , STML , DVAX , CHRS )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

LXRX : 5.28 (-0.94%)
STML : 13.47 (-2.53%)
RGEN : 86.80 (-1.13%)
Stemline Therape is Among the Companies in the Biotechnology Industry with the Best Relative Performance (STML , BCRX , CCXI , ALXN , PTLA )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

STML : 13.47 (-2.53%)
BCRX : 3.39 (-2.59%)
CCXI : 8.16 (-1.45%)
Top 5 Companies in the Biotechnology Industry with the Best Relative Performance (PGNX , STML , CHRS , BPMC , BCRX )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

PGNX : 5.26 (-1.50%)
STML : 13.47 (-2.53%)
CHRS : 17.68 (-2.21%)
Top 5 Companies in the Biotechnology Industry with the Best Relative Performance (MNTA , SGEN , STML , NVTA , EPZM )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

STML : 13.47 (-2.53%)
MNTA : 9.60 (-5.42%)
SGEN : 75.07 (-2.05%)
Sangamo Therapeu has the Best Relative Performance in the Biotechnology Industry (SGMO , CHRS , STML , SPPI , ARWR)

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

SGMO : 11.60 (-4.53%)
ARWR : 29.17 (-1.55%)
STML : 13.47 (-2.53%)
CHRS : 17.68 (-2.21%)
Stemline Therape Has Returned 26.2% Since SmarTrend Recommendation (STML)

SmarTrend identified an Uptrend for Stemline Therape (NASDAQ:STML) on January 18th, 2019 at $10.45. In approximately 2 months, Stemline Therape has returned 26.18% as of today's recent price of $13.18....

STML : 13.47 (-2.53%)
Look for Shares of Stemline Therape to Potentially Pullback after Yesterday's 2.57% Rise

Stemline Therape (NASDAQ:STML) traded in a range yesterday that spanned from a low of $12.85 to a high of $13.18. Yesterday, the shares gained 2.6%, which took the trading range above the 3-day high...

STML : 13.47 (-2.53%)
Research Report Identifies Oracle, Realty Income, Stemline Therapeutics, WhiteHorse Finance, EverQuote, and Sanderson Farms with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Oracle Corporation (NYSE:ORCL),...

SAFM : 129.98 (-1.16%)
WHF : 14.27 (+0.49%)
STML : 13.47 (-2.53%)
ORCL : 57.54 (-1.00%)
EVER : 14.47 (+0.21%)
O : 68.74 (-1.94%)
27.8% Return Seen to Date on SmarTrend Stemline Therape Call (STML)

SmarTrend identified an Uptrend for Stemline Therape (NASDAQ:STML) on January 18th, 2019 at $10.45. In approximately 2 months, Stemline Therape has returned 27.81% as of today's recent price of $13.35....

STML : 13.47 (-2.53%)
Top 5 Companies in the Biotechnology Industry with the Best Relative Performance (CCXI , STML , CYTK , NBIX , DVAX )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

CYTK : 11.14 (-0.80%)
STML : 13.47 (-2.53%)
CCXI : 8.16 (-1.45%)
Stemline Therapeutics to Participate in Panel on Myeloid Tumors at the 31st Annual ROTH Conference

Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that Ivan Bergstein,...

STML : 13.47 (-2.53%)
Stemline Therapeutics: 4Q Earnings Snapshot

NEW YORK (AP) _ Stemline Therapeutics Inc. (STML) on Friday reported a loss of $26.6 million in its fourth quarter.

STML : 13.47 (-2.53%)

Van Meerten Stock Picks

Leading Economic Indicator ALERT!
I very closely follow the Conference Board's Leading Economic Indicators.
IVV -1.75
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar